Biotech Values

[DewDiligence]

REGN/SNY—If ODYSSEY OUTCOMES by itself will cost $500M (#msg-81212052), how much will the suite of approximately six phase-3 trials for REGN727 announced in #msg-73969663 cost?

John LaMattina tweeted that his best guess is $800M; if this is accurate, the phase-3 cost for REGN727 will be on a par with PFE’s Torcetrapib and will be among the most expensive phase-3 programs ever.